A drug safety evaluation of abiraterone acetate in the treatment of prostate cancer. Issue 9 (2nd September 2019)

• Record Type: Journal Article
• Authors: Castellan, Pietro; Castellucci, Roberto; Marchioni, Michele; De Nunzio, Cosimo; Tema, Giorgia; Primiceri, Giulia; Schips, Luigi; Cindolo, Luca
• Is Part Of: Expert opinion on drug safety. Volume 18:Issue 9(2019)
• Page Start: 759
• Page End: 767
• Publication Date: 2019-09-02
• Subjects: Abiraterone acetate -- metastatic prostate cancer -- androgen receptor -- toxicity -- castration-resistant prostate cancer -- hormone-naïve prostate cancer; Drugs -- Side effects -- Periodicals; Drugs -- Toxicology -- Periodicals; Chemotherapy -- Periodicals; 615.704
• DOI: 10.1080/14740338.2019.1648428
• Languages: English
• ISSNs: 1474-0338

Abstract

ABSTRACT: Introduction : To evaluate the safety profile characteristics of abiraterone acetate (AA) in the treatment of metastatic prostate cancer (mPCa). Areas covered : In this literature review the authors evaluate safety data from phase III trials investigating the combination of abiraterone acetate plus prednisone (AAP) in patients with metastatic prostate cancer. In particular, the aim was to clarify its toxicity profile, long-term exposure impact, and the correlation with general health-related quality of life (HRQoL). Expert opinion : Based on the studies reviewed, it appears that abiraterone acetate has favourable outcomes, is effective and well tolerated, mostly in asymptomatic or slightly symptomatic patients, and has recognised toxicity profile characteristics. Incidence of adverse events (AEs), such as mineralocorticoid- and corticosteroid-releated AEs, and hepatotoxicity is well known and widely described. Understanding the toxicity profile of AA could assist decision-making in clinical practice.